A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes

M Böhm, WJ Locke, RL Sutherland, JG Kench… - Oncogene, 2009 - nature.com
M Böhm, WJ Locke, RL Sutherland, JG Kench, SM Henshall
Oncogene, 2009nature.com
GATA-2, a member of the GATA family of transcription factors, is involved in androgen
receptor (AR) signaling, however, little is known regarding its role in prostate cancer. Here,
we report that GATA-2 is expressed in a substantial proportion of prostate cancers and that
high expression of GATA-2 is associated with biochemical recurrence and distant metastatic
progression in a validation set of 203 cancers. In vitro data show that GATA-2 is directly
recruited to the promoter region of the AR upon androgen stimulation of LNCaP prostate …
Abstract
GATA-2, a member of the GATA family of transcription factors, is involved in androgen receptor (AR) signaling, however, little is known regarding its role in prostate cancer. Here, we report that GATA-2 is expressed in a substantial proportion of prostate cancers and that high expression of GATA-2 is associated with biochemical recurrence and distant metastatic progression in a validation set of 203 cancers. In vitro data show that GATA-2 is directly recruited to the promoter region of the AR upon androgen stimulation of LNCaP prostate cancer cells with 5α-dihydroxytestosterone (DHT) for 24 h. Ectopic GATA-2 expression causes the induction of AR transcript levels under androgen-depleted conditions (P< 0.05). The expression of the AR target gene, AZGP1, is induced upon androgen stimulation and this effect is repressed by GATA-2. In contrast, GATA-2 significantly increases transcript levels of KLK2, which increases further in a time-dependent manner on DHT treatment and in the presence of GATA-2. These results indicate that upregulation of GATA-2 may contribute to the progression to aggressive prostate cancer through modulation of expression of AR and key androgen-regulated genes, one of which, AZGP1, is associated with the progression to metastatic disease.
nature.com